Cognition Therapeutics, Inc.
CGTX
$0.3529
$0.033510.49%
| Weiss Ratings | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.60 | |||
| Price History | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.53% | |||
| 30-Day Total Return | -22.42% | |||
| 60-Day Total Return | -50.05% | |||
| 90-Day Total Return | -12.21% | |||
| Year to Date Total Return | -51.20% | |||
| 1-Year Total Return | -83.11% | |||
| 2-Year Total Return | -79.72% | |||
| 3-Year Total Return | -88.90% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -89.17% | |||
| 52-Week Low % Change | 4.69% | |||
| Price | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.95 | |||
| 52-Week Low Price | $0.31 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | May 23, 2024 | |||
| Valuation | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 19.79M | |||
| Enterprise Value | -4.40M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.88 | |||
| Earnings Per Share Growth | 1.84% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.02 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.35 | |||
| Enterprise Value/EBITDA (TTM) | 0.08 | |||
| Enterprise Value/EBIT | 0.08 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 44.68M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 412 481 2210 | |||
| Address | 2500 Westchester Ave. Purchase, NY 10577 | |||
| Website | www.cogrx.com | |||
| Country | United States | |||
| Year Founded | 2007 | |||
| Profitability | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -103.15% | |||
| Return on Equity | -- | |||
| Income Statement | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -53.86M | |||
| EBIT (TTM) | -53.97M | |||
| Net Income (TTM) | -33.97M | |||
| Net Income Avl. to Common (TTM) | -33.97M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 3.67% | |||
| EPS Diluted (TTM) | -0.88 | |||
| EPS Diluted Growth (Q YOY) | 34.01% | |||
| Balance Sheet | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 25.01M | |||
| Cash Per Share (Q) | $0.56 | |||
| Total Current Assets (Q) | 29.56M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 18.75M | |||
| Current Ratio (Q) | 2.653 | |||
| Book Value Per Share (Q) | $0.31 | |||
| Total Assets (Q) | 30.23M | |||
| Total Current Liabilities (Q) | 11.14M | |||
| Total Debt (Q) | 814.00K | |||
| Total Liabilities (Q) | 11.48M | |||
| Total Common Equity (Q) | 18.75M | |||
| Cash Flow | CGTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -4.00K | |||
| Cash from Financing (TTM) | 23.57M | |||
| Net Change in Cash (TTM) | -4.91M | |||
| Levered Free Cash Flow (TTM) | -36.65M | |||
| Cash from Operations (TTM) | -28.47M | |||
